目的 探讨卡度尼利单抗致不良反应的特点，为其临床安全用药提供参考。方法 检索中国知网、万方数据、维普网、PubMed、Web of Science文献数据库中卡度尼利单抗致药品不良反应案例报道，对纳入文献进行统计分析。结果 共纳入16篇共计22例患者。男女各11例，年龄在34～81岁；60岁以上发生不良反应的患者15例（68.18%），其中8例（36.36%）患者存在合并用药；发生时间为用药后1 d～9个月，主要集中在前3个月内；20例（90.91%）患者经停药及对症处理后均好转，5例（22.73%）患者未提及后续是否继续使用卡度尼利单抗。不良反应累及多个器官或系统，以皮肤及附件（36.36%）最多，其次为心血管系统（31.82%）和内分泌系统（18.18%）。结论 卡度尼利单抗致不良反应可发生在各年龄段，以用药后3个月内发生为主，主要累及皮肤及附件、心血管和内分泌系统等。临床工作者应加强对卡度尼利单抗不良反应发生情况及临床特征的认识，确保临床用药安全。

Objective To explore the characteristics of adverse drug reaction induced by cadonilimab and provide a reference for clinically safe medication. Methods Case reports of adverse reactions caused by cadonilimab were retrieved from CNKI, Wanfang Data, VIP, PubMed, and Web of Science literature databases and analyzed statistically. Results A total of 22 patients were included in 16 papers. 11 men and 11 women, aged 34 — 81 years old. 15 Patients over 60 years old (68.18%) had adverse reactions, of which 8 patients (36.36%) had drug combination. The occurrence time was from 1 d to 9 months after medication, mainly concentrated in the first 3 months; 20 patients (90.91%) were improved after withdrawal and symptomatic treatment, and 5 patients (22.73%) did not mention whether to continue to use cardonilizumab. Adverse reactions involved multiple organs or systems, most of which were skin and adnexa (36.36%), followed by cardiovascular system (31.82%) and endocrine system (18.18%). Conclusion Adverse drug reaction caused by cadonilimab can occur in all ages, mainly within 3 months after medication and mainly involve the skin tissue, cardiovascular system, and endocrine system, etc. Clinicians should strengthen their understanding of the occurrence and clinical characteristics of adverse reactions of cadonilimab, and ensure clinical drug safety.

R979.1